U.S. abortion opponents express mounting frustration regarding President Donald Trump’s administration’s inaction on regulating abortion pills prescribed online, which they believe undermines state abortion bans.
A recent court ruling in a lawsuit initiated by the Louisiana attorney general against Trump’s Food and Drug Administration highlighted this tension, indicating the state’s strong case while allowing telehealth prescriptions of mifepristone to continue for now.
Push for FDA Action
Anti-abortion groups are urging the FDA to expedite its review of mifepristone, seeking restrictions that could prevent its prescription through telehealth platforms. The administration has stated that such reviews require time.
While these groups have largely targeted the FDA, they have not focused criticism on the Republican president, whose Supreme Court appointments facilitated the 2022 ruling that overturned Roe v. Wade. However, the administration’s requests to delay judicial rulings in Louisiana and similar cases have incited anger among some activists.
Kristi Hamrick, a spokesperson for Students for Life of America, expressed frustration, stating, ‘The stall tactics are beyond frustrating.’ She suggested that the administration could block the pills from being mailed by altering its interpretation of a 19th-century law.
Court Ruling Insights
U.S. District Judge David Joseph, nominated by Trump, issued a mixed ruling in a case brought by Louisiana Attorney General Liz Murrill and a woman alleging coercion into taking mifepristone. The ruling underscored the plaintiffs’ likelihood of success due to demonstrated ‘irreparable harm’ from the pill’s availability.
Judge Joseph declined to grant a request to block telehealth prescriptions during the ongoing litigation but mandated the FDA to report back within six months on its review of the drug.
Following this ruling, Murrill indicated plans to appeal to the U.S. 5th Circuit Court of Appeals to expedite the process.
Political Ramifications
Family Research Council President Tony Perkins commended Murrill’s actions, noting widespread surprise among constituents that abortion rates have not decreased since the Supreme Court ruling. He cautioned against any dampening of enthusiasm among conservative voters ahead of the midterm elections.
Conversely, some groups are adopting a more cautious stance. Madison LaClare, director of federal government affairs at National Right to Life, expressed trust in the administration’s review process, while Marjorie Dannenfelser, president of SBA Pro-Life America, emphasized the opportunity for the administration to prioritize women’s safety.
Recent electoral trends suggest that support for maintaining abortion access is gaining momentum, with voters favoring abortion rights in 14 out of 17 states where the issue has appeared on ballots since the overturning of Roe.
Rachel Rebouche, a professor at the University of Texas School of Law, noted a growing consensus against abortion bans in the country.
FDA’s Commitment to Review
In a statement responding to inquiries, the FDA confirmed it is reviewing mifepristone’s safety, emphasizing the need for thorough data collection and evaluation before any potential rule changes regarding the drug’s prescription.
The agency acknowledged that such studies could take over a year but aims to expedite the process. The FDA did not clarify when the review commenced.
Mifepristone has remained a focal point for anti-abortion activists since Trump returned to office, with Health and Human Services Secretary Robert F. Kennedy Jr. facing repeated inquiries about the drug during his confirmation hearing.
Frustration has been evident among anti-abortion advocates, particularly after the FDA approved an additional generic version of mifepristone last fall.
The drug, approved in 2000, is commonly used in conjunction with another medication, misoprostol, to terminate early pregnancies. Initial FDA restrictions were imposed due to rare instances of excessive bleeding, limiting its prescription to certified physicians and requiring in-person consultations. These requirements were lifted during the COVID-19 pandemic, based on extensive studies indicating that women could safely use the pill without direct supervision.